证券代码：600422 证券简称：昆药集团 公告编号：2025-040号 昆药集团股份有限公司十一届七次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 1、 关于公司 2025 年半年度报告及摘要的议案（公司 2025 年半年度报告及摘要刊登 于上海证券交易所网站 www.sse.com.cn） 本议案已经公司十一届董事会审计与风险控制委员会 2025 年第四次会议审议通 过，并同意提交公司董事会审议。 同意：9 票 反对：0 票 弃权：0 票 2、 关于聘请公司 2025 年度审计机构的议案（详见《昆药集团关于续聘会计师事务 所的公告》） 本议案已经公司十一届董事会审计与风险控制委员会 2025 年第四次会议审议通 过，并同意提交公司董事会审议。 同意：9 票 反对：0 票 弃权：0 票 此议案审议通过，还须提交公司股东大会审议。 3、 关于调整公司组织架构的议案 为深化组织重塑，支撑战略达成，根据业务需求，调整公司组织架构，明确新架 构部门职责。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 ...

昆药集团股份有限公司2025 年半年度报告 公司代码：600422 公司简称：昆药集团 昆药集团股份有限公司 2025 年半年度报告 1 / 188 昆药集团股份有限公司2025 年半年度报告 √适用 □不适用 本报告涉及的公司未来计划、发展战略等前瞻性描述因存在不确定性，不构成公司对投资者 的实质承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人颜炜、主管会计工作负责人孙志强及会计机构负责人（会计主管人员）杨学炳 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提 ...

Group 1 - The company reported a revenue of 3.351 billion yuan for the first half of 2025, representing a year-on-year decrease of 11.68% [1] - The net profit attributable to shareholders of the listed company was 198 million yuan, down 26.88% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 151 million yuan, a year-on-year decline of 5.57% [1] - The basic earnings per share were 0.26 yuan [1]

Core Viewpoint - Kunming Pharmaceutical Group (600422.SH) reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 3.351 billion yuan, a year-on-year decrease of 11.68% [1] - The net profit attributable to shareholders was 198 million yuan, down 26.88% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 150 million yuan, reflecting a year-on-year decline of 5.57% [1] - Basic earnings per share were reported at 0.26 yuan [1]

天眼查商业履历信息显示，昆药集团股份有限公司，成立于1995年，位于昆明市，是一家以从事医药制 造业为主的企业。企业注册资本75697.5757万人民币，实缴资本34113.0177万人民币。公司法定代表人 为颜炜。 通过天眼查大数据分析，昆药集团股份有限公司共对外投资了45家企业，参与招投标项目5000次，知识 产权方面有商标信息222条，专利信息465条，此外企业还拥有行政许可341个。 金融界消息 截至2025年8月14日收盘，昆药集团（600422）报收于14.53元，下跌0.27%，换手率 1.56%，成交量11.78万手，成交金额1.71亿元。 资金流向方面，今日主力资金净流出2274.31万元，占比成交额13.28%。其中，超大单净流出952.83万 元、占成交额5.56%，大单净流出1321.48万元、占成交额7.71%，中单净流出流入755.16万元、占成交 额4.41%，小单净流入1519.15万元、占成交额8.87%。 昆药集团最新一期业绩显示，截至2025一季报，公司营业总收入16.08亿元、同比减少16.53%，归属净 利润9048.23万元，同比减少31.06%，扣非净利润7206 ...

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in A-share traditional Chinese medicine companies is 730,900 yuan [1] - The top three highest-paid CFOs are from Jichuan Pharmaceutical, Yiling Pharmaceutical, and Dong'e Ejiao, with salaries of 1.78 million yuan, 1.74 million yuan, and 1.71 million yuan respectively [1] Group 2 - CFOs aged 50-60 constitute 44% of the market, while those aged 40-50 account for 42% [1] - The educational background of CFOs shows that 55% hold a bachelor's degree, and 33% have a master's degree [1] - The largest salary decrease was observed for Zhang Shuyuan from Jilin Aodong, with a year-on-year decline of 66.13%, while the largest increase was for Sun Zhiqiang from Kunming Pharmaceutical, with a year-on-year increase of 283.57% [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1][2] - Among the CFOs, those aged 50-60 constitute 44% of the market, while those aged 40-50 account for 42%, and only 12% are aged 40 or below [1] - The educational background of CFOs shows that 55% hold a bachelor's degree, while 33% have a master's degree, and only 2% have a technical secondary school education [1] Group 2 - The average annual salary of CFOs in the A-share traditional Chinese medicine sector is 730,900 yuan [2] - The salary distribution indicates that 44% of CFOs earn below 500,000 yuan, while 28% earn between 500,000 and 1 million yuan, and another 28% earn above 1 million yuan [2] - The top three highest-paid CFOs are from Jichuan Pharmaceutical, Yiling Pharmaceutical, and Dong'e Ejiao, with salaries of 1.78 million yuan, 1.74 million yuan, and 1.71 million yuan respectively [2]

Group 1 - The core viewpoint of the news is that Kunming Pharmaceutical Group Co., Ltd. has experienced a decline in both revenue and net profit in its latest quarterly report, indicating potential challenges in its financial performance [1][3] - As of August 5, 2025, the company's stock price closed at 14.75 yuan, down 1.14%, with a trading volume of 132,800 hands and a transaction amount of 196 million yuan [1] - The latest quarterly report shows total operating revenue of 1.608 billion yuan, a year-on-year decrease of 16.53%, and a net profit attributable to shareholders of 90.4823 million yuan, down 31.06% year-on-year [1] Group 2 - The company has made significant investments, with a total of 45 external investments and participation in 5,000 bidding projects [2] - In terms of intellectual property, the company holds 222 trademark registrations and 464 patents, along with 341 administrative licenses [2] - The company's financial ratios indicate a current ratio of 1.827, a quick ratio of 1.488, and a debt-to-asset ratio of 45.99% [1]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (27 individuals, 39%), between 500,000-1,000,000 yuan (29 individuals, 42%), between 1,000,000-2,000,000 yuan (10 individuals, 15%), between 2,000,000-3,000,000 yuan (2 individuals, 3%), and above 3,000,000 yuan (1 individual, 1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earners and Investor Relations - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu (2.5587 million yuan) - Cao Wei from Jichuan Pharmaceutical (2.4107 million yuan) - Yu Jie from Tian Shi Li (2.525 million yuan) - Wu Rui from Yiling Pharmaceutical (1.89 million yuan) - Jiang Xianhong from Yibai Pharmaceutical (1.3935 million yuan) [7] - The frequency of investor meetings varies significantly among companies, with 41 companies hosting fewer than 10 meetings annually (59%), 17 companies holding 10-100 meetings (25%), 9 companies conducting 100-300 meetings (13%), and 2 companies having 300-1000 meetings (3%) [7] Most Active Companies in Investor Relations - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical (410 meetings) - Qizheng Tibetan Medicine (404 meetings) - Yunnan Baiyao (298 meetings) - Jinghua Pharmaceutical (221 meetings) - Pian Zai Huang (207 meetings) [9]